Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03951519
Other study ID # GUINOT 2018-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 24, 2019
Est. completion date January 30, 2020

Study information

Verified date May 2019
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In ICU and operating theatre, fluid expansion is the main hemodynamic therapeutic. The objective of fluid expansion is to increase cardiac output thus arterial oxygen delivery to match patient's oxygen consumption. To date, it has been shown that all fluid expansion solutions may have side effects (hydro-electrolytic disorder, renal failure, hydro-sodium overload, etc.) that may limit their use.

Human digestive system physiologically ensures the absorption of oral water and hydration of the human body. Water is quickly absorbed by the digestive tract with a peak between 15 and 20 minutes. It has demonstrated that oral water remains the best hydration solution that have an effect on plasma volume expansion and cardiovascular system during exercise. While the cardiovascular effect of fluid expansion by saline serum is well known (venous return, preload and cardiac output), that of oral water vary in the literature depending on the physiological state of the patient and the clinical state. Oral water can change cardiac output and blood pressure through various physiological effects: increased blood volume, recruitment of splanchnic blood volume, and peripheral vasoconstriction. Usually, ICU patients have feeding through nasogastric tube.

To date, no study has studied the effect of a given amount of enteral cardiovascular system in ICU patients. The objective of this study is to describe the effect of oral water administration on the cardiovascular system of patients during the optimization and/or hemodynamic stabilization phase. The comparison of groups (water/ physiological saline) would allow us: (1) to describe the cardiovascular effects of water in the resuscitation patient, (2) to compare these cardiovascular effects with those of saline solution, (3) to have the data to design further study.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Close family member has given written consent for patient included in emergency

- Intubated-ventilated patient in controlled volume mode

- Normothermal patient (36.5-37.5°C)

- Adult patient in intensive care for whom the attending physician has decided to give fluid expansion because of acute circulatory failure (systolic blood pressure < 90 mmHg, and/or mean blood pressure < 65 mmHg, and/or the need for infusion of vasopressor amines, and/or skin mottles, and/or diuresis < 0.5 mL/kg/h for a duration of = 2 hours, and/or arterial lactate level > 2 mmol/L) (21),

- Patient with a variation OF SV over 10% with PLR,

- Echogenic patient,

- Patient with a regular sinus rhythm,

- Patient with a nasogastric tube.

Exclusion Criteria:

- Person subject to a legal protection measure (curatorship, guardianship)

- Person subject to a measure to safeguard justice

- Condition contraindicating the use of the oral route,

- Patient not affiliated or not covered by the national health system,

- Pregnant, parturient or breastfeeding woman,

- Hemodynamically unstable patient (variation of more than 10% in blood pressure),

- Arrhythmia-like rhythm disorder by atrial fibrillation,

- Modification of therapies (sedation, catecholamines) during the study period,

- Modification of the ventilatory parameters.

- Heart failure

- Oedemato-ascitic insufficiency of cirrhosis

- Changes in drug doses

Study Design


Related Conditions & MeSH terms

  • Intubated-ventilated Patients in the Intensive Care Unit

Intervention

Other:
oral administration of water
Volume expansion via 500 mL of water administered by the patient's nasogastric tube
administration of saline solution
Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route

Locations

Country Name City State
France Chu Dijon Bourogne Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary systolic ejection volume variation in systolic ejection volume between base (time 1) and end of filling (time 2), expressed as a percentage. 60 minutes
Secondary Blood pressure immediately, 30 and 60 minutes after fluid administration
Secondary Cardiac output immediately, 30 and 60 minutes after fluid administration,
Secondary volume of systolic ejections immediately, 30 and 60 minutes after fluid administration
Secondary arterial lactate level immediately after filling, 60 minutes after fluid administration,
Secondary Hourly diuresis 60 minutes after fluid administration
Secondary change in DO2 after filling, 60 minutes after fluid administration
Secondary change in VO2 after filling, 60 minutes after fluid administration
Secondary number ofAdverse effects of water administration (nausea, vomiting), "through study completion, an average of 1 year".
Secondary number Adverse effects of saline administration (natremia, chloremia, acute pulmonary edema, renal failure). "through study completion, an average of 1 year".